Detalhe da pesquisa
1.
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
JAMA
; 329(18): 1567-1578, 2023 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37159034
2.
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis.
ERJ Open Res
; 10(1)2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38288082
3.
Intermittent or daily montelukast versus placebo for episodic asthma in children.
Ann Allergy Asthma Immunol
; 106(6): 518-26, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21624752
4.
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.
NPJ Vaccines
; 5(1): 112, 2020 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335092
5.
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
BMJ Open Respir Res
; 6(1): e000422, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31179008
6.
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.
Adv Ther
; 36(11): 3059-3070, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31565781
7.
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
Lancet Diabetes Endocrinol
; 7(12): 899-911, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31676222
8.
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Clin Drug Investig
; 26(2): 63-74, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17163237
9.
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
Maturitas
; 48(3): 243-51, 2004 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15207890
10.
Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
J Bone Miner Res
; 29(8): 1786-94, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24643905
11.
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
J Clin Endocrinol Metab
; 98(2): 571-80, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23337728
12.
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
J Bone Miner Res
; 26(2): 242-51, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20740685
13.
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
J Bone Miner Res
; 25(5): 937-47, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19874198
14.
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
J Rheumatol
; 36(8): 1705-14, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19487264
15.
Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Arthritis Rheum
; 48(4): 1102-8, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12687554